Literature DB >> 12472906

Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments.

Félix Hernández1, José Borrell, Carmen Guaza, Jesús Avila, José J Lucas.   

Abstract

Deregulation of glycogen synthase kinase-3 (GSK-3) activity in neurones has been postulated as a key feature in Alzheimer's disease (AD) pathogenesis. This was further supported by our recent characterization of transgenic mice that conditionally over-express GSK-3beta in hippocampal and cortical neurones. These mice, designated Tet/GSK-3beta, showed many of the biochemical and cellular aspects of AD neuropathology such as tau hyperphosphorylation and somatodendritic localization, decreased nuclear beta-catenin, neuronal death and reactive gliosis. Tet/GSK-3beta mice, however, did not show tau filament formation up to the latest tested age of 3 months at least. Here we report spatial learning deficits of Tet/GSK-3beta mice in the Morris water maze. In parallel, we also measured the increase in GSK-3 activity while further exploring the possibility of tau filament formation in aged mice. We found a significant increase in GSK-3 activity in the hippocampus of Tet/GSK-3beta mice whereas no tau fibrils could be found even in very old mice. These data reinforce the hypothesis of GSK-3 deregulation in AD pathogenesis, and suggest that Tet/GSK-3beta mice can be used as an AD model and, most remarkably, can be used to test the therapeutic potential of the selective GSK-3 inhibitors that are currently under development. Additionally, these experiments suggest that destabilization of microtubules and alteration of intracellular metabolic pathways contribute to AD pathogenesis independent of toxicity triggered by the aberrant tau deposits.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12472906     DOI: 10.1046/j.1471-4159.2002.01269.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  112 in total

1.  Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease.

Authors:  B DaRocha-Souto; M Coma; B G Pérez-Nievas; T C Scotton; M Siao; P Sánchez-Ferrer; T Hashimoto; Z Fan; E Hudry; I Barroeta; L Serenó; M Rodríguez; M B Sánchez; B T Hyman; T Gómez-Isla
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

2.  [Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].

Authors:  A Schneider; P Falkai; A Papassotiropoulos
Journal:  Nervenarzt       Date:  2010-11       Impact factor: 1.214

Review 3.  A meeting to remember: meeting on memory and related disorders.

Authors:  Gregory P Gasic; Angel Barco; Jesús Avila; Juan Lerma
Journal:  EMBO Rep       Date:  2006-07-14       Impact factor: 8.807

Review 4.  The role of inflammatory processes in Alzheimer's disease.

Authors:  G Joseph Broussard; Jennifer Mytar; Rung-chi Li; Gloria J Klapstein
Journal:  Inflammopharmacology       Date:  2012-04-26       Impact factor: 4.473

5.  Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments.

Authors:  Ling-Qiang Zhu; Shao-Hui Wang; Dan Liu; Yang-Yang Yin; Qing Tian; Xiao-Chuan Wang; Qun Wang; Jian-Guo Chen; Jian-Zhi Wang
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

Review 6.  The role of GSK-3 in synaptic plasticity.

Authors:  S Peineau; C Bradley; C Taghibiglou; A Doherty; Z A Bortolotto; Y T Wang; G L Collingridge
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

7.  Neuronal induction of the immunoproteasome in Huntington's disease.

Authors:  Miguel Díaz-Hernández; Félix Hernández; Ester Martín-Aparicio; Pilar Gómez-Ramos; María A Morán; José G Castaño; Isidro Ferrer; Jesús Avila; José J Lucas
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

Review 8.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

9.  Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery.

Authors:  Xue-Yang Jiang; Ting-Kai Chen; Jun-Ting Zhou; Si-Yu He; Hong-Yu Yang; Yao Chen; Wei Qu; Feng Feng; Hao-Peng Sun
Journal:  ACS Med Chem Lett       Date:  2018-02-09       Impact factor: 4.345

10.  Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.

Authors:  Valentine Lahmy; Johann Meunier; Susanna Malmström; Gaelle Naert; Laurent Givalois; Seung Hyun Kim; Vanessa Villard; Alexandre Vamvakides; Tangui Maurice
Journal:  Neuropsychopharmacology       Date:  2013-03-14       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.